Arvinas (ARVN) vs Oculis (OCS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Arvinas (ARVN) has outperformed Oculis (OCS) over the past year, losing 43.9% versus a loss of 63.3%. Over five years, OCS leads with a -27.3% price change compared with -91.8% for ARVN. Arvinas is the larger company by market cap ($423.0 million vs $393.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | OCS |
|---|---|---|
| Share price | $6.46 | $7.06 |
| Market cap | $423.03M | $393.35M |
| 1-day change | -4.15% | -5.11% |
| YTD return | -45.53% | -64.65% |
| 1-year return | -43.92% | -63.34% |
| 5-year return | -91.75% | -27.29% |
| EPS (TTM) | $-0.08 | $-1.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $262.60M | — |
| Revenue growth (YoY) | -0.30% | — |
| Net income (latest FY) | $-80.80M | — |
| Operating margin | -45.13% | — |
| Net margin | -30.77% | — |
| 52-week high | $14.51 | $34.48 |
| 52-week low | $6.33 | $6.78 |
| Distance from 52-week high | -55.48% | -79.52% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +116.72% | +407.79% |
| Average volume | 848.52K | 272.83K |
| Shares outstanding | 65.49M | 55.72M |
| Employees | 246 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARVN has outperformed OCS by 19.4 percentage points over the past year.
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
ARVN vs OCS FAQ
Which is bigger, Arvinas or Oculis?
Arvinas (ARVN) is larger, with a market capitalization of $423.03M compared with $393.35M for Oculis (OCS).
Which stock has performed better over the past year, ARVN or OCS?
ARVN returned -43.92% over the past 12 months, compared with -63.34% for OCS (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and Oculis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.